Heron Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Heron Therapeutics Inc HRTX.OQ reported a quarterly adjusted loss of 2 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -6 cents. The mean expectation of four analysts for the quarter was for a loss of one cent per share. Wall Street expected results to range from -2 cents tozero cents per share.

• Revenue rose 3.3% to $37.20 million from a year ago; analysts expected $38.08 million.

• Heron Therapeutics Inc's reported EPS for the quarter was a loss of 2 cents​.

• The company reported a quarterly loss of $2.38 million.

• Heron Therapeutics Inc shares had fallen by 36.2% this quarter and lost 13.7% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 25% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Heron Therapeutics Inc is $5.00, about 73.6% above its last closing price of $1.32

This summary was machine generated from LSEG data August 11 at 12:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)